IN2015DN03203A - - Google Patents
Info
- Publication number
- IN2015DN03203A IN2015DN03203A IN3203DEN2015A IN2015DN03203A IN 2015DN03203 A IN2015DN03203 A IN 2015DN03203A IN 3203DEN2015 A IN3203DEN2015 A IN 3203DEN2015A IN 2015DN03203 A IN2015DN03203 A IN 2015DN03203A
- Authority
- IN
- India
- Prior art keywords
- binding agent
- impurities
- mixture
- cytotoxic agent
- cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261709871P | 2012-10-04 | 2012-10-04 | |
| PCT/US2013/063503 WO2014055893A1 (en) | 2012-10-04 | 2013-10-04 | Use of an ion exchange membrane to remove impurities from cell-binding agent cytotoxic agent conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN03203A true IN2015DN03203A (pt) | 2015-10-02 |
Family
ID=50435480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3203DEN2015 IN2015DN03203A (pt) | 2012-10-04 | 2013-10-04 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20150307596A1 (pt) |
| EP (1) | EP2903450A4 (pt) |
| JP (1) | JP2015535215A (pt) |
| CN (1) | CN105208876A (pt) |
| AU (1) | AU2013326897A1 (pt) |
| CA (1) | CA2886996A1 (pt) |
| HK (1) | HK1213148A1 (pt) |
| IL (1) | IL238111A0 (pt) |
| IN (1) | IN2015DN03203A (pt) |
| MX (1) | MX2015004258A (pt) |
| RU (1) | RU2015116883A (pt) |
| SG (1) | SG11201502430QA (pt) |
| WO (1) | WO2014055893A1 (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2390826T3 (es) | 2005-08-24 | 2012-11-16 | Immunogen Inc | Procedimiento para preparar conjugados de fármaco purificados |
| HUE043645T2 (hu) | 2009-06-03 | 2019-08-28 | Immunogen Inc | Konjugációs módszerek |
| PL2691155T3 (pl) | 2011-03-29 | 2019-06-28 | Immunogen, Inc. | Otrzymywanie koniugatu majtansynoidu przeciwciała jednoetapowym sposobem |
| US10035817B2 (en) * | 2012-10-04 | 2018-07-31 | Immunogen, Inc. | Method of purifying cell-binding agent-cytotoxic agent conjugates with a PVDF membrane |
| GB201616758D0 (en) * | 2016-10-03 | 2016-11-16 | Ge Healthcare Bio Sciences Ab | Novel chromatography media |
| CN108549763B (zh) * | 2018-04-09 | 2021-06-01 | 电子科技大学 | 一种用于离子推进器数值模拟的电荷交换碰撞mcc方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005532258A (ja) * | 2002-01-03 | 2005-10-27 | スミスクライン・ビーチャム・コーポレイション | 免疫コンジュゲートの調製方法 |
| US20090068178A1 (en) * | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
| US20110166319A1 (en) * | 2005-02-11 | 2011-07-07 | Immunogen, Inc. | Process for preparing purified drug conjugates |
| WO2006086733A2 (en) * | 2005-02-11 | 2006-08-17 | Immunogen, Inc. | Process for preparing maytansinoid antibody conjugates |
| ES2390826T3 (es) * | 2005-08-24 | 2012-11-16 | Immunogen Inc | Procedimiento para preparar conjugados de fármaco purificados |
| HUE043645T2 (hu) * | 2009-06-03 | 2019-08-28 | Immunogen Inc | Konjugációs módszerek |
| PL2691155T3 (pl) * | 2011-03-29 | 2019-06-28 | Immunogen, Inc. | Otrzymywanie koniugatu majtansynoidu przeciwciała jednoetapowym sposobem |
-
2013
- 2013-10-04 CN CN201380061514.1A patent/CN105208876A/zh active Pending
- 2013-10-04 WO PCT/US2013/063503 patent/WO2014055893A1/en active Application Filing
- 2013-10-04 IN IN3203DEN2015 patent/IN2015DN03203A/en unknown
- 2013-10-04 SG SG11201502430QA patent/SG11201502430QA/en unknown
- 2013-10-04 RU RU2015116883A patent/RU2015116883A/ru not_active Application Discontinuation
- 2013-10-04 CA CA 2886996 patent/CA2886996A1/en not_active Abandoned
- 2013-10-04 JP JP2015535827A patent/JP2015535215A/ja active Pending
- 2013-10-04 MX MX2015004258A patent/MX2015004258A/es unknown
- 2013-10-04 EP EP13843881.7A patent/EP2903450A4/en not_active Withdrawn
- 2013-10-04 AU AU2013326897A patent/AU2013326897A1/en not_active Abandoned
- 2013-10-04 US US14/430,744 patent/US20150307596A1/en not_active Abandoned
-
2015
- 2015-04-02 IL IL238111A patent/IL238111A0/en unknown
-
2016
- 2016-02-04 HK HK16101358.6A patent/HK1213148A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN105208876A (zh) | 2015-12-30 |
| CA2886996A1 (en) | 2014-04-10 |
| RU2015116883A (ru) | 2016-11-27 |
| WO2014055893A1 (en) | 2014-04-10 |
| EP2903450A1 (en) | 2015-08-12 |
| JP2015535215A (ja) | 2015-12-10 |
| SG11201502430QA (en) | 2015-04-29 |
| EP2903450A4 (en) | 2016-05-11 |
| US20150307596A1 (en) | 2015-10-29 |
| AU2013326897A1 (en) | 2015-05-07 |
| HK1213148A1 (zh) | 2016-06-30 |
| IL238111A0 (en) | 2015-05-31 |
| MX2015004258A (es) | 2015-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN03202A (pt) | ||
| EP4253395A3 (en) | Processes for the preparation of carbohydrate conjugated rna agents | |
| MX2021005426A (es) | Ciclodextrina y formulaciones de conjugados anticuerpo-farmaco. | |
| PH12015500243A1 (en) | Glycoconjugation processes and compositions | |
| MX2016017355A (es) | Lipido que comprende acido docosapentaenoico. | |
| NZ708727A (en) | Conjugate compounds | |
| IN2015DN03203A (pt) | ||
| MX2015005792A (es) | Compuestos de conjugado antisentido anti apob. | |
| MD20150091A2 (ro) | Compuşi antivirali | |
| CA2830549C (en) | Methods and compositions for preparing noribogaine from voacangine | |
| IN2015DN03327A (pt) | ||
| MX2013000958A (es) | Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma. | |
| MX347882B (es) | Procedimiento mejorado para preparar (3e, 7e)-homofarnesol. | |
| PH12014502032A1 (en) | Treatment of brain cancer | |
| MX2013013649A (es) | Compuestos de quinona para tratar enfermedades mediadas por ape1. | |
| MX2018005785A (es) | Conjugados de anticuerpo anti-cd22-maytansina y metodos de uso de los mismos. | |
| PH12014501367A1 (en) | Processes for making magnolol and derivatives thereof | |
| PH12014501327A1 (en) | Processes for making magnolol analogs | |
| GEP201706708B (en) | Isoxazolidine derivatives | |
| WO2014159501A3 (en) | Processes for preparing tetrahydroisoquinolines | |
| IN2012DE00826A (pt) | ||
| WO2014030173A3 (en) | Improved process for preparation of atazanavir bisulfate | |
| IN2014KN02683A (pt) | ||
| IN2013CH04314A (pt) | ||
| SG10201803880TA (en) | Stable compositions of neuroactive peptides |